$REVB News

Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026

Revelation Biosciences Announces 1-For-7 Reverse Stock Split, Effective Oct. 20

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Revelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN Study For Evaluating Gemini In Patients With Acute Kidney Injury

REVB Approaching a Critical Inflection Point

Revelation Biosciences (NASDAQ:REVB) Surges on Pipeline Progress Despite Q2 Earnings Miss

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

Revelation Biosciences Cites Independent Market Assessment Indicating A $94B Total Addressable Market For Its Gemini Kidney Treatment

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revelation Biosciences Announces Adoption of Stockholder Rights Plan

Revelation Biosciences' Board Implements Shareholder Rights Plan, Declares Dividend Distribution Of One Right For Each Outstanding Common Stock

Revelation Biosciences Expands Acute Kidney Injury Advisory Board

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation

REVB Poised for Big Year

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Revelation Biosciences Q1 EPS $(2.71) Misses $(1.55) Estimate

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board